Outdated Drivers Are Slowing You Down
One free scan finds every outdated or missing driver and matches the right update for your exact hardware.Free scan · exact hardware matchWindows Errors? Fix Them Before They Spread
Repair common Windows errors and clear accumulated junk for a smoother, more stable PC - no reinstall needed.Free scan · no reinstallPancreatic tumors that respond to a RAS- or KRAS-targeted drug can still find a way around it. The evidence points to two broad routes. Tumor cells can acquire genetic changes that restore growth signals. Or they can shift into a different cell state that depends less on KRAS. Current tests do not catch every escape route, so no single mechanism explains every case.
The title doesn’t name a drug. The best current match is daraxonrasib (RMC-6236), a RAS(ON) inhibitor. The National Cancer Institute’s pancreatic cancer overview, updated September 23, 2026, says the FDA approved it on August 26, 2026, for advanced, previously treated pancreatic cancer (NCI). That is an inference from the title, and these findings don’t apply to every “breakthrough” pancreatic drug. Much of the resistance work below comes from other KRAS inhibitors and from lab models, and it is labeled that way.
As an Amazon Associate I earn from qualifying purchases.
Why a targeted drug can stop working at all
A tumor is not one uniform population. It is a mix of cells that differ in their DNA and in which genes they switch on. A drug that blocks a growth pathway kills or slows the cells that depend on it. Any cells that depend on it less are left behind, and they can regrow. That is the logic behind the clues below.
Quick wins for a faster PC:
Clear out junk files and repair common Windows errorsFree Scan →Scan for outdated or missing drivers - takes under a minuteDriver Scan →Repair Windows errors before they cause bigger problemsFix Now →The target here is well chosen. NCI says targeted therapy research focuses on altered KRAS because more than 90% of pancreatic cancers carry KRAS mutations. NCI also recommends tumor biomarker testing for advanced or metastatic disease (NCI, 2026). A common target is also why resistance is so closely studied. The target is hit hard, so the survivors are the cells that found a workaround.
#1 Best Overall
A note on scope and evidence
NCI’s overview covers several types of pancreatic cancer. Most of the KRAS-inhibitor resistance findings discussed here concern pancreatic ductal adenocarcinoma (PDAC). The evidence also comes from three different levels:
- Patient samples: blood-based tumor DNA from people treated in trials.
- Laboratory and mouse models: useful for mechanisms, but not a measure of how patients will respond.
- Hypotheses: ideas for future combinations that have not been shown to work in people.
Clue 1: Tumors acquire new genetic changes
Andrew Aguirre, M.D., Ph.D., of Dana-Farber Cancer Institute, put it plainly to NCI: “We’ve seen several different genetic alterations emerge that cause tumors to become resistant” to KRAS inhibitors (NCI Cancer Currents, August 20, 2024).
A 2026 Nature Medicine paper looks at this directly for daraxonrasib. According to its published abstract, the authors analyzed more than 800 genes in paired circulating tumor DNA (ctDNA) samples. One sample was taken before treatment and one at the end of treatment. The samples came from 44 phase 1/2 trial patients whose tumors acquired resistance. The title says the findings “guide rational combination therapy strategies” (Nature Medicine, September 2026).
Rank #2
Two cautions apply to that figure:
- “More than 800 genes” and “44 patients” describe the study’s scope and cohort. They are not a resistance rate.
- The full paper’s breakdown of which mechanisms were most common was not available when this was written, so the share of patients with each mechanism isn’t established here.
What can be said is that the genetic route is plausible and documented for KRAS inhibitors generally, and that it is heterogeneous. There is no single “resistance mutation” to point to.
Clue 2: Tumor cells may change state instead of changing DNA
Pancreatic tumors contain cells in different gene-expression states. In work summarized by NCI, treatment with a KRAS inhibitor was followed by a larger share of classical-state cells, and these appeared to rely less on KRAS to survive. In that scenario the tumor escapes by changing which program its cells run. It doesn’t need a new mutation in every case.
Christine Alewine, M.D., Ph.D., of NCI’s Center for Cancer Research, interpreted two studies this way: “Both of these studies seem to be saying that, while there are some genetic changes that can occur in cells that make up pancreatic tumors, this underlying ability to change their cell state appears to be a main thing driving resistance” (NCI, 2024).
This is an expert’s reading of laboratory and mouse findings at that time. It has not been shown to explain every patient’s resistance to daraxonrasib, and it is not settled clinical fact.
Recommended Free Tools
Clue 3: Gene tests may be missing part of the picture
A review of clinical and preclinical work on KRAS inhibition in Cancer Discovery (2024) reports a notable gap. In one ctDNA-based analysis, no putative genetic resistance mechanism was identified in 54% of PDAC cases. The authors offered two explanations: detection may be incomplete, or non-genetic mechanisms may be involved (Cancer Discovery, 2024).
“Not identified” does not prove a non-genetic cause. It could equally mean the test missed a change. The figure also belongs to that analysis and its methods, not to all patients taking daraxonrasib.
This is why a blood test is not a complete answer to “why did it stop working?” ctDNA can reveal some DNA changes. The available evidence does not show that it finds every mechanism, or that it can predict when resistance will appear in an individual patient.
Clue 4: Adding chemotherapy may help, at least in mice
If resistance comes from cells with different survival programs, attacking them from more than one direction is a logical response. In two studies summarized by NCI, the experimental KRAS inhibitor MRTX1133 was combined with gemcitabine and nab-paclitaxel in mouse models. The combination reduced tumor growth more than either approach alone. In one model the average tumor-size reduction was about 60% greater than with the KRAS inhibitor alone. The investigators discussed exploiting different cellular programs and cell-state vulnerabilities (NCI, 2024).
Free tools Windows power users keep installed
One-click scans. No signup required.
Alewine’s takeaway was: “for now, it looks like adding on to standard chemotherapy, rather than eliminating it, may turn into our best weapon against pancreatic cancer.”
Keep the limits in view. These were mouse models of a different drug, MRTX1133. The results don’t establish an optimal human regimen, and they don’t show that a combination prevents resistance to daraxonrasib. The 2026 Nature Medicine paper frames its resistance findings as guiding rational combinations, which makes this an active direction rather than a proven answer.
Independent reader supportYour contribution helps us test, update, and keep practical guides available for everyone.How the approaches and evidence compare
| Comparison | What it shows | Limit |
|---|---|---|
| Direct KRAS/RAS inhibition vs. chemotherapy | Inhibitors block the mutated pathway that drives most pancreatic cancers. Chemotherapy is a broader cell-killing approach. | The sources here don’t establish which is better for a given patient. |
| Single agent vs. combination | In mice, a KRAS inhibitor plus gemcitabine and nab-paclitaxel beat either approach alone. | Animal evidence, with a different inhibitor (MRTX1133). |
| DNA-level resistance vs. cell-state adaptation | ctDNA can reveal acquired genetic changes. Cell-state shifts were seen in lab and mouse work and wouldn’t show up as new mutations. | In one ctDNA analysis, 54% of PDAC cases had no identified genetic mechanism. |
| Patient samples vs. models | The daraxonrasib study used paired ctDNA from 44 trial patients. The cell-state and combination work used cells and mice. | Model findings may not carry over to patients. |
What is still unknown
- Which resistance mechanism dominates among patients treated with daraxonrasib, and what share develop each one.
- A validated clinical test that predicts resistance before it appears.
- Whether cell-state change, as seen in models, is a major driver in people on daraxonrasib.
- A proven drug sequence or combination that prevents or delays resistance.
What this means for patients and families
Daraxonrasib is approved in the U.S. for advanced, previously treated pancreatic cancer. It is not a cure, and the approval is not for every stage (NCI, 2026). Resistance is a recognized limit of targeted therapy. It reflects tumor biology, not something the patient did wrong. Mechanistic findings like these can’t be turned into personal advice. Whether to repeat tumor or blood testing, change treatment, or join a trial testing combinations is a decision for the oncology team.
Frequently Asked Questions
Does the title mean daraxonrasib specifically?
The title names no drug. Daraxonrasib is the closest current match because NCI reports its FDA approval in August 2026. The resistance clues are specific to KRAS and RAS inhibitors, not to every pancreatic cancer drug.
Will a blood test tell me why my treatment stopped working?
It may reveal some genetic changes, but it can miss others. It also can’t show non-genetic cell-state shifts directly. Ask your oncologist whether repeat testing would change your options.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
